Novartis Settles Short-Lived Suit Over Janssen's Psoriasis Drug Promo
The companies resolve litigation as competition in the psoriasis drug market intensifies; there are now 12 approved products in the US, with TNF-alpha inhibitors still dominating.
You may also be interested in...
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
With Spravato's launch underway, J&J reports that 800 sites have been certified to administer the depression drug. Newer drugs drove pharma sales in the first quarter, while US sales of Zytiga declined 55% due to generic competition.
US judge is 'troubled' by Janssen's omission of relevant safety data in summary of Tremfya v. Cosentyx study, but finds Novartis claim of irreparable harm is 'too speculative.'